Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18418863 | 0.79 | MAPT (0.42) | ALDH1A1LMNAMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL21847658 | 0.79 | PDK1 (0.37) | ALDH1A1TDP1LMNAKDM4EMAPT | |
| SCHEMBL21805105 | 0.78 | LMNA (0.47) | ALDH1A1LMNAMAPTL3MBTL1TXNRD1 | |
| SCHEMBL27718447 | 0.77 | GPR35 (0.34) | ALDH1A1LMNAKDM4EMAPTL3MBTL1 | |
| SCHEMBL10781069 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TDP1LMNAMERTKKDM4E | |
| SCHEMBL20364258 | 0.76 | ALDH1A1 (0.33) | ALDH1A1LMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL20516141 | 0.75 | LMNA (0.33) | ALDH1A1LMNAKDM4EMAPTCYP3A4 | |
| SCHEMBL25690402 | 0.74 | MAPT (0.42) | ALDH1A1TDP1LMNAMAPTL3MBTL1 | |
| SCHEMBL266568 | 0.74 | — | — | |
| SCHEMBL27786236 | 0.73 | MAPT (0.43) | ALDH1A1MAPTHTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-217449821-U | 3-methoxy-4-nitro-1H-pyrazole nitration mixed acid preparation device | 上海晋鲁医药科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12559442-B2 | Use of N-functionalized alkoxy pyrazole compounds as nitrification inhibitors | BASF SE (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-4253375-B1 | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025228892-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-10-30 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630539-B2 | Amide compound, pharmaceutical composition and use thereof | JAK2, JAK1, JAK3 | ALDH1A1 3620/4885TDP1 4239/4885LMNA 4268/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 2233/4885TDP1 2346/4885LMNA 4606/4885 |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 2345/4885TDP1 2639/4885LMNA 4624/4885 |
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PARK7 | ALDH1A1 2229/4885TDP1 250/4885LMNA 541/4885 |
| US-20250333398-A1 | MONOARYL AND HETARYL SUBSTITUTED INDAZOLES AND BENZIMIDAZOLES AS STING ANTAGONISTS AND THE USE THEREOF AS MEDICAMENT | STING1, MAVS, TBK1 | ALDH1A1 3967/4885TDP1 742/4885LMNA 1762/4885 |
| US-12559442-B2 | Use of N-functionalized alkoxy pyrazole compounds as nitrification inhibitors | NAT1, CBR1, CBR3 | ALDH1A1 1195/4885TDP1 1478/4885LMNA 1306/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | ALDH1A1 2505/4885TDP1 2762/4885LMNA 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.